Search
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma.
Chlormezanone
go.drugbank.com/drugs/DB01178ApprovedWithdrawnA non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
Synonyms: 2-(p-chlorphenyl)-3-methyl-1,3-perhydrothiazin-4-on-1,1-dioxideBerberine
go.drugbank.com/drugs/DB04115ApprovedInvestigationalWithdrawnAn alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. … It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Categories: Heterocyclic Compounds with 4 or More RingsTalazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. … [L47236] Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 [A260346] and by the EMA in June 2019.[L47296] It was approved by Health Canada in September 2020.
Categories: P-glycoprotein substrates with a Narrow Therapeutic IndexBenzhydrocodone
go.drugbank.com/drugs/DB15465Approved[A182177] Benzhydrocodone is indicated for use in the short-term management of pain. … Benzhydrocodone is a benzylic prodrug of hydrocodone.[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigationalRelebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to [avibactam]. … [label] It is considered to be a last-line treatment option and gained FDA approval as part of the combination product RecarbrioⓇ in July 2019.[L7568]
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePamidronic acid
go.drugbank.com/drugs/DB00282ApprovedInvestigationalPamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]
Categories: Drugs for Treatment of Bone DiseasesProducts: Pamidronate Disodium for Injection, MENEDRON-L 15 MG IV ENJEKSİYONLUK LİYOFİLİZE TOZ İÇEREN FLAKON (4 FLAKON)Droxidopa
go.drugbank.com/drugs/DB06262ApprovedInvestigationalDroxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. … Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout
Synonyms: L-DOPS, L-DihydroxyphenylserineResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalOn March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD … Resmetirom is a thyroid hormone receptor-beta (THR-beta) agonist.
Raxtozinameran
go.drugbank.com/drugs/DB18228ApprovedInvestigationalIt works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]
Synonyms: messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)